We are live on ! Find out more
TAK icon

Takeda Pharmaceutical
TAK

390 hedge funds and large institutions have $3.64B invested in Takeda Pharmaceutical in 2019 Q1 according to their latest regulatory filings, with 308 funds opening new positions, 62 increasing their positions, 14 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,322% more first-time investments, than exits

New positions opened: 308 | Existing positions closed: 9

1,500% more funds holding in top 10

Funds holding in top 10: 1 → 16 (+15)

343% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 14

319% more funds holding

Funds holding: 93 → 390 (+297)

300% more capital invested

Capital invested by funds: $910M → $3.64B (+$2.73B)

4.64% more ownership

Funds ownership: 6.8% → 11.43% (+4.6%)

1% less call options, than puts

Call options by funds: $94.4M | Put options by funds: $95.5M

Holders
390
Holders Change
+297
Holders Change %
+319.35%
% of All Funds
8.44%
Holding in Top 10
16
Holding in Top 10 Change
+15
Holding in Top 10 Change %
+1,500%
% of All Funds
0.35%
New
308
Increased
62
Reduced
14
Closed
9
Calls
$94.4M
Puts
$95.5M
Net Calls
-$1.07M
Net Calls Change
-$4.21M

Top Buyers

Rank Fund Capital Flow
1
GCM
Glenview Capital Management
New York
+$525M
2
PC
Paulson & Co
New York
+$267M
3
BG
Baupost Group
Massachusetts
+$215M
4
AC
Adelphi Capital
United Kingdom
+$187M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$152M

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$200M
2
Citigroup
Citigroup
New York
-$127M
3
Bank of America
Bank of America
North Carolina
-$90.5M
4
Goldman Sachs
Goldman Sachs
New York
-$47.1M
5
CS
Credit Suisse
Switzerland
-$23.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
201
Diker Management
New York
$237K +$235K +11,656 New
MML Investors Services
202
MML Investors Services
Massachusetts
$236K +$233K +11,566 New
TCOT
203
Trust Company of Toledo
Ohio
$231K +$229K +11,365 New
Squarepoint
204
Squarepoint
New York
$230K +$227K +11,281 New
DBIA
205
Dumont & Blake Investment Advisors
New Jersey
$230K +$227K +11,300 New
AP
206
Advisor Partners
California
$228K +$226K +11,214 New
KLC
207
Knowledge Leaders Capital
Colorado
$226K +$223K +11,076 New
AWA
208
Alaska Wealth Advisors
Alaska
$223K +$220K +10,923 New
RJT
209
Raymond James Trust
Florida
$222K +$220K +10,927 New
CIBC Private Wealth Group
210
CIBC Private Wealth Group
Georgia
$221K +$218K +10,852 New
SF
211
Synovus Financial
Georgia
$219K +$216K +10,727 New
BF
212
BOK Financial
Oklahoma
$211K +$208K +10,335 New
Cambridge Investment Research Advisors
213
Cambridge Investment Research Advisors
Iowa
$211K +$208K +10,352 New
AIM
214
Axiom Investment Management
New York
$209K +$207K +10,268 New
PCMI
215
Paradigm Capital Management Inc
New York
$205K +$203K +10,068 New
RHBC
216
R.H. Bluestein & Co
Michigan
$205K +$203K +10,068 New
Toronto Dominion Bank
217
Toronto Dominion Bank
Ontario, Canada
$203K +$200K +9,950 New
Parallax Volatility Advisers
218
Parallax Volatility Advisers
California
$194K +$192K +9,546 New
SFSIG
219
San Francisco Sentry Investment Group
California
$176K +$174K +8,663 New
BHMP
220
Bardin Hill Management Partners
New York
$168K +$166K +8,233 New
AF
221
Advisornet Financial
Minnesota
$159K +$157K +7,783 New
BBNA
222
Bremer Bank National Association
Minnesota
$158K +$173K +8,593 New
LC
223
Lindbrook Capital
California
$155K +$154K +7,631 New
RFC
224
Regions Financial Corp
Alabama
$137K +$135K +6,708 New
HNB
225
Huntington National Bank
Ohio
$134K +$133K +6,587 New
7 8
9
10 11

TAK Hedge Fund Activity: Q1 2019 in Review

390 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q1 2019, worth a combined $3.64B — up 300% from $910M a quarter earlier.

Buyers outnumbered sellers: 308 funds opened new TAK positions and 9 closed out — a net gain of 299 holders — while 62 added to existing stakes and 14 trimmed.

The largest buyer was Glenview Capital Management, opening a new position worth an estimated $525M. The largest seller was UBS Group, cutting an estimated $200M.

  • 390 institutional investors held Takeda Pharmaceutical (TAK) as of Q1 2019, up from 93 in Q4 2018.
  • Funds reported $3.64B of Takeda Pharmaceutical stock for Q1 2019, up 300% quarter-over-quarter.
  • 308 funds opened new Takeda Pharmaceutical positions in Q1 2019 and 9 closed out, a net change of +299 holders.
  • The largest Takeda Pharmaceutical buyer in Q1 2019 was Glenview Capital Management, an estimated $525M added.
  • The largest Takeda Pharmaceutical seller in Q1 2019 was UBS Group, an estimated $200M sold.

Based on aggregated 13F filings for Q1 2019.